NEW YORK (GenomeWeb) – Bruker said today that it has acquired informatics firm Scils and reagents manufacturer InVivo Biotech Services.
Both acquisitions add to Bruker's life sciences portfolio with Scils bringing expertise in areas including analysis and visualization of imaging mass spectrometry data and InVivo providing expertise in manufacturing monoclonal antibodies and recombinant proteins as well as custom immunoassays and research kits.
Bremen, Germany-based Scils offers several products, Scils Lab, Scils Lab 3D, and Scils Cloud, to support MALDI mass spec imaging work. According to Bruker, the company expects these to complement its MALDI imaging systems, including its Molecular DrugImager Solution, which applies MALDI imaging to pharma research, and its MALDI Tissuetyper, which is aimed at translational pathology research.
"Our goal is to advance the [mass spec imaging] field and enable a deeper understanding of the spatial distribution of various molecules in the disciplines of biomarker discovery, pharma drug tissue distribution studies, all the way to translational research in anatomical pathology and future diagnostic applications," Rohan Thakur, executive vice president at Bruker Daltonics, said in a statement.
Hennigsdorf, Germany-based InVivo specializes in biotech services with a primary focus on antibody and immunoassay development. Bruker said the company, which will continue to operate under the InVivo name and its current management team, will support its efforts to develop new content for its MALDI Biotyper platform, including assays for antibiotic resistance and PCR-based syndromic panels.
"We are systematically building up infrastructure to support our rapidly growing consumables business, especially in the field of microbiology and to prepare the market development in anatomical and molecular pathology," Wolfgang Pusch, executive vice president at Bruker Daltonics said. "Together with our recently announced acquisition in the field of multiplex PCR-based microbiology testing, the InVivo Biotech acquisition is expected to greatly accelerate our assay and consumables business expansion."
InVivo had 2016 revenues of around $5 million.
Financial and other terms of the acquisitions were not disclosed.